News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Scopa James Paul
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Disposed/sold 15,199 shares
@ $0
Disposed/sold 25,722 shares
@ $0
Disposed/sold 12,096 options to buy
@ $17, valued at
$205.6k
Disposed/sold 8,261 options to buy
@ $17, valued at
$140.4k
Disposed/sold 13,800 options to buy
@ $17, valued at
$234.6k
Disposed/sold 21,250 options to buy
@ $14.98, valued at
$318.3k
|
|
| 08/03/2023 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Gifted 220 shares
@ $0
Gifted 2,200 shares
@ $0 |
|
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/13/2023 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Gifted 300 shares
@ $0 |
|
| 05/02/2023 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Gifted 6,923 shares
@ $0
Gifted 6,923 shares
@ $0 |
|
| 03/21/2023 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Gifted 30,719 shares
@ $0
Gifted 30,719 shares
@ $0
Sold 10,000 shares
@ $29.05, valued at
$290.5k
|
|
| 06/27/2022 |
4
| Scopa James Paul (Director) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.34, valued at
$20.1k
|
|
| 06/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2022 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Granted 21,250 options to buy
@ $14.98, valued at
$318.3k
|
|
| 02/11/2022 |
5
| Scopa James Paul (Director) has filed a Form 5 on DICE Therapeutics, Inc. |
| 11/17/2021 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Sold 50,000 shares
@ $2.18, valued at
$109k
|
|
| 09/16/2021 |
4
| Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Bought 6,000 shares
@ $17, valued at
$102k
Granted 12,096 options to buy
@ $17, valued at
$205.6k
Granted 8,261 options to buy
@ $17, valued at
$140.4k
Granted 8,200 options to buy
@ $17, valued at
$139.4k
Granted 5,600 options to buy
@ $17, valued at
$95.2k
|
|
| 09/14/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/14/2021 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Granted 40,000 options to buy
@ $3.7, valued at
$148k
|
|
| 04/27/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/27/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/25/2020 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Granted 30,000 options to buy
@ $25.64, valued at
$769.2k
|
|
| 05/05/2020 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Exercised 23,334 shares
@ $6.48, valued at
$151.2k
Exercised 23,334 options to buy
@ $6.48, valued at
$151.2k
|
|
| 02/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2019 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Granted 33,750 options to buy
@ $13.41, valued at
$452.6k
|
|
| 08/02/2019 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Granted 11,250 options to buy
@ $13.41, valued at
$150.9k
|
|
| 05/06/2019 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Bought 20,000 shares
@ $6.71, valued at
$134.2k
|
|
| 05/03/2019 |
4
| Scopa James Paul (Director) has filed a Form 4 on Adverum Biotechnologies, Inc.|
Txns:
| Granted 70,000 options to buy
@ $6.48, valued at
$453.6k
|
|
| 05/03/2019 |
3
| Scopa James Paul (Director) has filed a Form 3 on Adverum Biotechnologies, Inc. |
| 06/25/2018 |
4
| Scopa James Paul (Director) has filed a Form 4 on Conatus Pharmaceuticals Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.99, valued at
$99.8k
|
|
| 06/26/2017 |
4
| Scopa James Paul (Director) has filed a Form 4 on Conatus Pharmaceuticals Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.96, valued at
$99.2k
|
|
| 09/29/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/24/2016 |
4
| Scopa James Paul (Director) has filed a Form 4 on Conatus Pharmaceuticals Inc. |
| 03/09/2016 |
4
| MPM BioVentures IV QP LP (10% Owner) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Converted 1,138,210 shares
@ $0
Converted 718,396 shares
@ $0
Converted 312,085 shares
@ $0
Converted 1,138,210 preferred shares
@ $0
Converted 718,396 preferred shares
@ $0
Converted 312,085 preferred shares
@ $0 |
|
| 03/02/2016 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
| 02/04/2016 |
4
| Scopa James Paul (Director) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Disposed/sold 1,776,692 shares
@ $0 |
|
| 10/20/2015 |
4
| MPM BIOVENTURES V, L.P. (10% Owner) has filed a Form 4 on Cerecor Inc.|
Txns:
| Converted 595,436 shares
@ $0
Converted 16,672,224 convertible preferred
@ $0 |
|
| 07/21/2015 |
4
| MPM BioVentures IV QP LP (10% Owner) has filed a Form 4 on CHIASMA, INC|
Txns:
| Converted 10,426 shares
@ $0
Converted 2,488,171 shares
@ $0
Converted 1,759,381 shares
@ $0
Converted 1,423,566 shares
@ $0
Converted 95,225 options to buy
@ $0
Converted 22,721,988 options to buy
@ $0
Converted 16,066,669 options to buy
@ $0
Converted 13,000,000 preferred shares
@ $0 |
|
|
|
|